Avid Bioservices Inc (CDMO)

[biopharm]

Scott Antonia : Peregrine Pharmaceuticals KOL

Oh my.... Dr. Scott Antonia knows very well the power of Bavituximab. Now if only Dr. Antonia had some type of incentive when he came on board PPHM as a KOL back in Dec 2013 ....

ooops, and maybe he does and a few dots to the puzzle thrown in all over the place here....

--------------------------------

Cellular Biomedicine Acquires CD40LGVAX Vaccine

June 12, 2015

Cellular Biomedicine Group Inc. (CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, has entered into an agreement to acquire from Blackbird Bio Finance University of South Florida's next generation GVAX vaccine's (CD40LGVAX) related technologies and know-how for an initial consideration of $2.5 million in cash and $1.75 million in shares of the company's common stock. CBMG will pay potentially more than $25 million in future milestones and royalty payments. As part of the transaction, CBMG will be the exclusive global licensee of the Licensor's related technologies and know-how, the progeny manufacturing rights with access to a master vaccine bank originating from the University of South Florida.

The inventor of CD40LGVAX, Scott Antonia, is currently the Department Chair of Thoracic Oncology and Program Leader of the Immuno-oncology Program at the Moffitt Cancer Center. Dr. Antonia ranks among the foremost experts in the world of immuno-oncology and is an active collaborator with large pharmaceutical companies. He is recognized as one of the world's leading authorities in the treatment of lung cancer with immunotherapeutics and has recently joined the Company's Scientific Advisory Board. Given the positive Phase I results of CD40LGVAX alone in non-small cell lung cancer (NSCLC), Dr. Antonia plans to combine the CD40LGVAX with a checkpoint inhibitor, anti-PD1 monoclonal antibody, Nivolumab, in a three patient lead-in Phase I clinical trial followed by a randomized Phase II clinical trial in the U.S. to evaluate the safety and efficacy of the combination in patients with Stage 4 unresectable non-small cell lung cancer. The clinical trials are expected to commence in the second half of 2015.

William (Wei) Cao, chief executive officer, Cellular Biomedicine Group, said, "This strategic acquisition will enable CBMG to broaden its product portfolio based on the acquired related technologies and know-how to augment our immuno-oncology platform portfolio, particularly cancer immunotherapy vaccine and combination technology platform. Fundamentally, it would transform CBMG into a global player with leading comprehensive cancer treatment programs.”

http://www.contractpharma.com/contents/view_breaking-news/2015-06-12/cellular-biomedicine-acquires-cd40lgvax-vaccine/

-----------------------------

Cellular Biomedicine Group Appoints Two New Members to Scientific Advisory Board

April 30, 2015

...
..
I am glad to see that Peregrine KOL Scott Antonia is being sought after by other bitech companies, but I also happened to notice William S. Cohen "recommends" William Cao - CEO of Cellular Biomedicine Group and lets hope Peregrine is aware of that.
...
..

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113351054&txt2find=william|cao

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113350628&txt2find=william|cao

---------------------------